Aartsma-Rus, A. and Corey, D. R. (2020). The 10th Oligonucleotide Therapy
Approved: Golodirsen for Duchenne Muscular Dystrophy. Nucleic Acid Ther. nat.2020.0845.
Acharyya, S., Butchbach, M. E. R., Sahenk, Z., Wang, H., Saji, M., Carathers, M., Ringel, M. D., Skipworth, R. J. E., Fearon, K. C. H., Hollingsworth, M. A., et al. (2005). Dystrophin glycoprotein complex dysfunction: A regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 8, 421–432.
Adams, M. E., Odom, G. L., Kim, M. J., Chamberlain, J. S. and Froehner, S. C. (2018). Syntrophin binds directly to multiple spectrin-like repeats in dystrophin and mediates binding of nNOS to repeats 16-17. Hum. Mol. Genet. 27, 2978–2985.
Ahn, A. H. and Kunkel, L. M. (1995). Syntrophin binds to an alternatively spliced exon of dystrophin. J. Cell Biol. 128, 363–371.
Amann, K. J., Renley, B. A. and Ervasti, J. M. (1998). A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction. J. Biol. Chem. 273, 28419–28423.
Anderson, J. E., Bressler, B. H. and Ovalle, W. K. (1988). Functional regeneration in the hindlimb skeletal muscle of the mdx mouse. J. Muscle Res. Cell Motil. 9, 499–515.
Anthony, K., Cirak, S., Torelli, S., Tasca, G., Feng, L., Arechavala-Gomeza, V., Armaroli, A., Guglieri, M., Straathof, C. S., Verschuuren, J. J., et al. (2011). Dystrophin quantification and clinical correlations in Becker muscular dystrophy: Implications for clinical trials. In Brain, pp. 3544– 3556. Oxford University Press.
Aoki, Y., Nakamura, A., Yokota, T., Saito, T., Okazawa, H., Nagata, T. and Takeda, S. (2010). In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol. Ther. 18, 1995–2005.
Argilés, J. M., Busquets, S., Toledo, M. and López-Soriano, F. J. (2009). The role of cytokines in cancer cachexia. Curr. Opin. Support. Palliat. Care 3, 263–268.
Awano, H., Matsumoto, M., Nagai, M., Shirakawa, T., Maruyama, N., Iijima, K., Nabeshima, Y. ichi and Matsuo, M. (2018). Diagnostic and clinical significance of the titin fragment in urine of Duchenne muscular dystrophy patients. Clin. Chim. Acta 476, 111–116.
Bañuelos, S., Saraste, M. and Carugo, K. D. (1998). Structural comparisons of calponin homology domains: Implications for actin binding. Structure 6, 1419–1431.
Beggs, A. H., Hoffman, E. P. and Kunkel, L. M. (1992). Additional dystrophin fragment in Becker muscular dystrophy may result from proteolytic cleavage at deletion junctions. Am. J. Med. Genet. 44, 378–381.
Bischoff, R. (1990). Interaction between satellite cells and skeletal muscle fibers. Development 109, 943–952.
Bodensteiner, J. B. and Engel, A. G. (1978). Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: A study of 567,000 muscle fibers in 114 biopsies. Neurology 28, 439–446. Camboni, M., Hammond, S., Martin, L. T. and Martin, P. T. (2012). Induction of a regenerative microenvironment in skeletal muscle is sufficient to induce embryonal rhabdomyosarcoma in p53-deficient mice. J. Pathol. 226, 40–9.
Campbell, K. P. and Kahl, S. D. (1989). Association of dystrophin and an integral membrane glycoprotein. Nature 338, 259–262.
Cerna, J., Cerecedo, D., Ortega, A., García-Sierra, F., Centeno, F., Garrido, E., Mornet, D. and Cisneros, B. (2006). Dystrophin Dp71f Associates with the β1-Integrin Adhesion Complex to Modulate PC12 Cell Adhesion. J. Mol. Biol. 362, 954–965.
Chamberlain, J. S., Metzger, J., Reyes, M., Townsend, D. W. and Faulkner, J. A. (2007). Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 21,2195–2204.
Chang, N. C., Sincennes, M.-C., Muñ Oz-Cá, P., Ming, H. and Rudnicki, M. A. (2018a). The Dystrophin Glycoprotein Complex Regulates the Epigenetic Activation of Muscle Stem Cell Commitment. Stem Cell 22, 755-768.e6.
Chang, N. C., Sincennes, M.-C., Chevalier, F. P., Brun, C. E., Lacaria, M., Segalés, J., Muñoz-Cánoves, P., Ming, H. and Rudnicki, M. A. (2018b). The Dystrophin Glycoprotein Complex Regulates the Epigenetic Activation of Muscle Stem Cell Commitment. Cell Stem Cell 22, 755- 768.e6.
Chiba, A., Matsumura, K., Yamada, H., Inazu, T., Shimizu, T., Kusunoki, S., Kanazawa, I., Kobata, A. and Endo, T. (1997). Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve αdystroglycan. The role of a novel O-mannosyl-type oligosaccharide in the binding of α-dystroglycan with laminin. J. Biol. Chem. 272, 2156–2162.
Cohen, J. (2018). In dogs, CRISPR fixes a muscular dystrophy. Science (80-. ). 361, 835.
Comi, G. P., Prelle, A., Bresolin, N., Moggio, M., Bardoni, A., Gallanti, A., Vita, G., Toscano, A., Ferro, M. T., Bordoni, A., et al. (1994). Clinical variability in becker muscular dystrophy genetic, biochemical and immunohistochemical correlates. Brain 117, 1–14.
Corrado, K., Rafael, J. A., Mills, P. L., Cole, N. M., Faulkner, J. A., Wang, K. and Chamberlain, J. S. (1996). Transgenic mdx mice expressing dystrophin with a deletion in the actin- binding domain display a “mild Becker” phenotype. J. Cell Biol. 134, 873–884.
Cottin, P., Poussard, S., Mornet, D., Brustis, J. J. J., Mohammadpour, M., Leger, J., Ducastaing, A., Momet, D., Brustis, J. J. J., Mohammadpour, M., et al. (1992). In vitro digestion of dystrophin by calcium-dependent proteases, calpains I and II. Biochimie 74, 565–570.
Cox, G. F. and Kunkel, L. M. (1997). Dystrophies and heart disease. Curr. Opin. Cardiol. 12, 329–343.
Cox, G. A., Sunada, Y., Campbell, K. P. and Chamberlain, J. S. (1994). Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy. Nat. Genet. 8, 333–339.
Crosbie, R. H., Lebakken, C. S., Holt, K. H., Venzke, D. P., Straub, V., Lee, J. C., Grady, R. M., Chamberlain, J. S., Sanes, J. R. and Campbell, K. P. (1999). Membrane targeting and stabilization of sarcospan is mediated by the sarcoglycan subcomplex. J. Cell Biol. 145, 153–165.
Dangain, J. and Vrbova, G. (1984). Muscle development in mdx mutant mice. Muscle Nerve 7, 700–704.
Daoud, F., Angeard, N., Demerre, B., Martie, I., Benyaou, R., Leturcq, F., Cossee, M., Deburgrave, N., Saillour, Y., Tuffery, S., et al. (2009). Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression. Hum. Mol. Genet. 18, 3779–3794.
Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., Schurra, C., Garré, M., Giovanni Nuciforo, P., Bensimon, A., et al. (2006). Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444, 638–642.
Dubowitz, V. and Crome, L. (1969). The central nervous system in duchenne muscular dystrophy. Brain 92, 805–808.
Dumont, N. A., Wang, Y. X., Von Maltzahn, J., Pasut, A., Bentzinger, C. F., Brun, C. E. and Rudnicki, M. A. (2015). Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat. Med. 21, 1455–1463.
Edmondson, D. G. and Olson, E. N. (1989). A gene with homology to the myc similarity region of MyoD1 is expressed during myogenesis and is sufficient to activate the muscle differentiation program. Genes Dev. 3, 628–640.
Ervasti, J. M. and Campbell, K. P. (1993). A role for the dystrophinglycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. 122, 809–823.
Ettinger, A. J., Feng, G. and Sanes, J. R. (1997). ε-sarcoglycan, a broadly expressed homologue of the gene mutated in limb-girdle muscular dystrophy 2d. J. Biol. Chem. 272, 32534–32538.
Fernandez, K., Serinagaoglu, Y., Hammond, S., Martin, L. T. and Martin, P. T. (2010). Mice Lacking Dystrophin or α Sarcoglycan Spontaneously Develop Embryonal Rhabdomyosarcoma with Cancer-Associated p53 Mutations and Alternatively Spliced or Mutant Mdm2 Transcripts. Am. J. Pathol. 176, 416–434.
Fiorillo, A. A., Heier, C. R., Novak, J. S., Tully, C. B., Brown, K. J., Uaesoontrachoon, K., Vila, M. C., Ngheim, P. P., Bello, L., Kornegay, J. N., et al. (2015). TNF-α-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy. Cell Rep. 12, 1678–1690.
Gailly, P., De Backer, F., Van Schoor, M. and Gillis, J. M. (2007). In situ measurements of calpain activity in isolated muscle fibres from normal and dystrophin-lacking mdx mice. J. Physiol. 582, 1261–1275.
Ganem, N. J. and Pellman, D. (2012). Linking abnormal mitosis to the acquisition of DNA damage. J. Cell Biol. 199, 871–881.
Gao, Z., Zhang, S. and Yang, G. (1998). [A study of p16 gene and its protein expression in rhabdomyosarcoma]. Zhonghua bing li xue za zhi = Chinese J. Pathol. 27, 290–3.
Hagiwara, Y., Yoshida, M., Nonaka, I. and Ozawa, E. (1989). Developmental expression of dystrophin on the plasma membrane of rat muscle cells. Protoplasma 151, 11–18.
Hara, E., Smith, R., Parry, D., Tahara, H., Stone, S. and Peters, G. (1996). Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 16, 859–867.
Hawkins, W. G., Hoos, A., Antonescu, C. R., Urist, M. J., Leung, D. H. Y., Gold, J. S., Woodruff, J. M., Lewis, J. J. and Brennan, M. F. (2001). Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer 91, 794–803.
Hoffman, E. P. and Kunkel, L. M. (1989). Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. Neuron 2, 1019–29.
Hoffman, E. P., Brown, R. H. and Kunkel, L. M. (1987). Dystrophin: The protein product of the duchenne muscular dystrophy locus. Cell 51, 919–928.
Hoffman, E. P., Fischbeck, K. H., Brown, R. H., Johnson, M., Medori, R., Loire, J. D., Harris, J. B., Waterston, R., Brooke, M., Specht, L., et al. (1988). Characterization of Dystrophin in Muscle-Biopsy Specimens from Patients with Duchenne’s or Becker’s Muscular Dystrophy. N. Engl. J. Med. 318, 1363–1368.
Hosaka, Y., Yokota, T., Miyagoe-Suzuki, Y., Yuasa, K., Imamura, M., atsuda, R., Ikemoto, T., Kameya, S. and Takeda, S. N. I. (2002). α1- Syntrophin-deficient skeletal muscle exhibits hypertrophy and aberrant formation of neuromuscular junctions during regeneration. J. Cell Biol. 158, 1097–1107.
Hugnot, J. P., Gilgenkrantz, H., Vincent, N., Chafey, P., Morris, G. E., Monaco, A. P., Berwald-Netter, Y., Koulakoff, A., Kaplan, J. C., Kahn, A., et al. (1992). Distal transcript of the dystrophin gene initiated from an alternative first exon and encoding a 75-kDa protein widely distributed in nonmuscle tissues. Proc. Natl. Acad. Sci. U. S. A. 89, 7506–7510.
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A. and Dracopoli, N. C. (1994). Germline p16 mutations in familial melanoma. Nat. Genet. 8, 15–21.
Ibraghimov-Beskrovnaya, O., Ervasti, J. M., Leveille, C. J., Slaughter, C. A., Sernett, S. W. and Campbell, K. P. (1992). Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 355, 696–702.
Ishikawa-Sakurai, M., Yoshida, M., Imamura, M., Davies, K. E. and Ozawa, E. (2004). ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to β-dystroglycan. Hum. Mol. Genet. 13, 693–702.
Kashi, V. P., Hatley, M. E. and Galindo, R. L. (2015). Probing for a deeper understanding of rhabdomyosarcoma: Insights from complementary model systems. Nat. Rev. Cancer 15, 426–439.
Kawaguchi, T., Niba, E. T. E., Rani, A. Q. M., Onishi, Y., Koizumi, M., Awano, H., Matsumoto, M., Nagai, M., Yoshida, S., Sakakibara, S., et al. (2018). Detection of dystrophin Dp71 in human skeletal muscle using an automated capillary western assay system. Int. J. Mol. Sci. 19,.
Kieny, P., Chollet, S., Delalande, P., Le Fort, M., Magot, A., Pereon, Y. and Perrouin Verbe, B. (2013). Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann. Phys. Rehabil. Med. 56, 443–454.
Kim, T. W., Wu, K., Xu, J. L. and Black, I. B. (1992). Detection of dystrophin in the postsynaptic density of rat brain and deficiency in a mouse model of Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U. S. A. 89, 11642–11644.
Koenig, M. and Kunkel, L. M. (1990). Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. J. Biol. Chem. 265, 4560–4566.
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kaariainen, H., et al. (1989). The molecular basis for duchenne versus becker muscular dystrophy: Correlation of severity with type of deletion. 45, 498–506.
Komulainen, J. and Vihko, V. (1998). The course of exercise-induced skeletal muscle fibre injury. In Oxidative Stress in Skeletal Muscle, pp. 59–73. Birkhäuser Basel.
Kumar, S., Perlman, E., Harris, C. A., Raffeld, M. and Tsokos, M. (2000). Myogenin is a Specific Marker for Rhabdomyosarcoma: An Immunohistochemical Study in Paraffin-Embedded Tissues.
Lai, K.-M. V., Gonzalez, M., Poueymirou, W. T., Kline, W. O., Na, E., Zlotchenko, E., Stitt, T. N., Economides, A. N., Yancopoulos, G. D. and Glass, D. J. (2004). Conditional Activation of Akt in Adult Skeletal Muscle Induces Rapid Hypertrophy. Mol. Cell. Biol. 24, 9295–9304.
Lai, Y., Thomas, G. D., Yue, Y., Yang, H. T., Li, D., Long, C., Judge, L., Bostick, B., Chamberlain, J. S., Terjung, R. L., et al. (2009). Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Invest. 119, 624–635.
Langenbach, K. J. and Rando, T. A. (2002). Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle and Nerve 26, 644–653.
Larcher, T., Lafoux, A., Tesson, L., Remy, S., Thepenier, V., François, V., Le Guiner, C., Goubin, H., Dutilleul, M., Guigand, L., et al. (2014). Characterization of Dystrophin Deficient Rats: A New Model for Duchenne Muscular Dystrophy. PLoS One 9, e110371.
Leibovitz, S., Meshorer, A., Fridman, Y., Wieneke, S., Jockusch, H., Yaffe, D. and Nudel, U. (2002). Exogenous Dp71 is a dominant negative competitor of dystrophin in skeletal muscle. Neuromuscul. Disord. 12, 836–44.
Lidov, H. G. W., Byers, T. J., Watkins, S. C. and Kunkel, L. M. (1990).
Localization of dystrophin to postsynaptic regions of central nervous system cortical neurons. Nature 348, 725–728.
Lim, K. R. Q., Maruyama, R. and Yokota, T. (2017). Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des. Devel. Ther. 11, 533–545.
Maruyama, N., Asai, T., Abe, C., Inada, A., Kawauchi, T., Miyashita, K.,
Maeda, M., Matsuo, M. and Nabeshima, Y. I. (2016). Establishment of a highly sensitive sandwich ELISA for the N-Terminal fragment of titin in urine. Sci. Rep. 6,.
Matsuo, M., Awano, H., Maruyama, N. and Nishio, H. (2019). Titin fragment in urine: A noninvasive biomarker of muscle degradation. In Advances in Clinical Chemistry, pp. 1–23. Academic Press Inc.
Mauro, A. Lo and Aliverti, A. (2016). Physiology of respiratory disturbances in muscular dystrophies. Breathe 12, 318–327.
Mauro, A. (1961). Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol. 9, 493–495.
McCourt, J. L., Talsness, D. M., Lindsay, A., Arpke, R. W., Chatterton, P. D., Nelson, D. M., Chamberlain, C. M., Olthoff, J. T., Belanto, J. J.,
McCourt, P. M., et al. (2018). Mouse models of two missense mutations in actin-binding domain 1 of dystrophin associated with Duchenne or Becker muscular dystrophy. Hum. Mol. Genet. 27, 451–462.
Melacini, P., Fanin, M., Danieli, G. A., Villanova, C., Martinello, F., Miorin, M., Freda, M. P., Miorelli, M., Mostacciuolo, M. L., Fasoli, G., et al. (1996). Myocardial involvement is very frequent among patients affected with subclinical Becker’s muscular dystrophy. Circulation 94, 3168–3175.
Meyer, W. H. and Spunt, S. L. (2004). Soft tissue sarcomas of childhood. Cancer Treat. Rev. 30, 269–280.
Min, Y. L., Li, H., Rodriguez-Caycedo, C., Mireault, A. A., Huang, J., Shelton, J. M., McAnally, J. R., Amoasii, L., Mammen, P. P. A., BasselDuby, R., et al. (2019). CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells. Sci. Adv. 5,.
Mizuno, Y., Yoshida, M., Nonaka, I., Hirai, S. and Ozawa, E. (1994). Expression of utrophin (dystrophin-related protein) and dystrophinassociated glycoproteins in muscles from patients with Duchenne muscular dystrophy. Muscle Nerve 17, 206–216.
Mokri, B. and Engel, A. G. (1975). Duchenne dystrophy: Electron microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber. Neurology 25, 1111–1120.
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H. and Kunkel, L.
M. (1988). An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2, 90–95.
Moxley, R. T., Ashwal, S., Pandya, S., Connolly, A., Florence, J., Mathews, K., Baumbach, L., McDonald, C., Sussman, M. and Wade, C. (2005). Practice Parameter: Corticosteroid treatment of Duchenne dystrophy - Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 64, 13–20.
Multhoff, G., Molls, M. and Radons, J. (2012). Chronic inflammation in cancer development. Front. Immunol. 2,.
Muntoni, F., Mateddu, A., Marchei, F., Clerk, A. and Serra, G. (1993).
Muscular weakness in the mdx mouse. J. Neurol. Sci. 120, 71–77.
Murakami, Y., Yada, E., Nakano, S. I., Miyagoe-Suzuki, Y., Hosoyama, T., Matsuwaki, T., Yamanouchi, K. and Nishihara, M. (2011). Establishment of bipotent progenitor cell clone from rat skeletal muscle. Anim. Sci. J. 82, 764–772.
Nakamura, K., Fujii, W., Tsuboi, M., Tanihata, J., Teramoto, N., Takeuchi, S., Naito, K., Yamanouchi, K. and Nishihara, M. (2015). Generation of muscular dystrophy model rats with a CRISPR/Cas system. Sci. Rep.
Nigro, G., Comi, L. I., Politano, L. and Bain, R. J. I. (1990). The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int. J. Cardiol. 26, 271–277.
Norwood, F. L. M., Sutherland-Smith, A. J., Keep, N. H. and KendrickJones, J. (2000). The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy. Structure 8, 481–491.
Parham, D. M. and Ellison, D. A. (2006). Rhabdomyosarcomas in adults and children: An update. Arch. Pathol. Lab. Med. 130, 1454–1465.
Passamano, L., Taglia, A., Palladino, A., Viggiano, E., D’Ambrosio, P., Scutifero, M., Cecio, M. R., Torre, V., De Luca, F., Picillo, E., et al. (2012). Improvement of survival in Duchenne Muscular Dystrophy: Retrospective analysis of 835 patients. Acta Myol. 31, 121–125.
Pasternak, C., Wong, S. and Elson, E. L. (1995). Mechanical function of dystrophin in muscle cells. J. Cell Biol. 128, 355–361.
Patrick, J. and Lindstrom, J. (1973). Autoimmune response to acetylcholine receptor. Science (80-. ). 180, 871–872.
Pearson, H. B., Perez-Mancera, P. A., Dow, L. E., Ryan, A., Tennstedt, P., Bogani, D., Elsum, I., Greenfield, A., Tuveson, D. A., Simon, R., et al. (2011). SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J. Clin. Invest. 121, 4257–4267.
Phelps, S. F., Hauser, M. A., Cole, N. M., Rafael, J. A., Hinkle, R. T., Faulkner, J. A. and Chamberlain, J. S. (1995). Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum. Mol. Genet. 4, 1251–1258.
Pramono, Z. A. D., Takeshima, Y., Alimsardjono, H., Ishii, A., Takeda, S. ichi and Matsuo, M. (1996). Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem. Biophys. Res. Commun. 226, 445–449.
Quelle, D. E., Cheng, M., Ashmun, R. A. and Sherr, C. J. (1997). Cancerassociated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc. Natl. Acad. Sci. U. S. A. 94, 669–673.
Reid, M. B. and Li, Y. P. (2001). Tumor necrosis factor-α and muscle wasting: A cellular perspective. Respir. Res. 2, 269–272.
Rentschler, S., Linn, H., Deininger, K., Bedford, M. T., Espanel, X. and Sudol, M. (1999). The WW domain of dystrophin requires EF-hands region to interact with β-dystroglycan. Biol. Chem. 380, 431–442.
Rommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N., Yancopoulos, G. D. and Glass, D. J. (2001). Mediation of IGF-1- induced skeletal myotube hypertrophy by Pl(3)K/Alt/mTOR and Pl(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3, 1009–1013.
Ruas, M. and Peters, G. (1998). The p16(INK4a)/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta - Rev. Cancer 1378,.
Rubin, B. P., Nishijo, K., Chen, H.-I. H., Yi, X., Schuetze, D. P., Pal, R., Prajapati, S. I., Abraham, J., Arenkiel, B. R., Chen, Q.-R., et al. (2011). Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell 19, 177–91.
Ruymann, F. B. and Grovas, A. C. (2000). Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Cancer Invest. 18, 223–241.
Rybakova, I. N., Amann, K. J. and Ervasti, J. M. (1996). A new model for the interaction of dystrophin with F-actin. J. Cell Biol. 135, 661–672.
Rybakova, I. N., Patel, J. R. and Ervasti, J. M. (2000). The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J. Cell Biol. 150, 1209–1214.
Sadoulet-Puccio, H. M., Rajala, M. and Kunkel, L. M. (1997). Dystrobrevin and dystrophin: An interaction through coiled-coil motifs. Proc. Natl. Acad. Sci. U. S. A. 94, 12413–12418.
Schofield, J. N., Górecki, D. C., Blake, D. J., Davies, K. and Edwards, Y. H. (1995). Dystroglycan mRNA expression during normal and mdx mouse embryogenesis: A comparison with utrophin and the apo-dystrophins. Dev. Dyn. 204, 178–185.
Sebire, N. J. and Malone, M. (2003). Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas. J. Clin. Pathol. 56, 412–416.
Sharpless, N. E., Ramsey, M. R., Balasubramanian, P., Castrillon, D. H. and DePinho, R. A. (2004). The differential impact of p16 INK4a or p19 ARF deficiency on cell growth and tumorigenesis. Oncogene 23, 379–385.
Shigemoto, K., Kubo, S., Mori, S., Yamada, S., Akiyoshi, T. and Miyazaki, T. (2010). Muscle weakness and neuromuscular junctions in aging and disease. Geriatr. Gerontol. Int. 10,.
Shimo, T., Hosoki, K., Nakatsuji, Y., Yokota, T. and Obika, S. (2018). A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping. J. Hum. Genet. 63, 365–375.
Shin, J., Tajrishi, M. M., Ogura, Y. and Kumar, A. (2013). Wasting mechanisms in muscular dystrophy. Int. J. Biochem. Cell Biol. 45, 2266–2279.
Sicinski, P., Geng, Y., Ryder-Cook, A. S., Barnard, E. A., Darlison, M. G. and Barnard, P. J. (1989). The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science (80-. ). 244, 1578–1580.
Simon, J. H., Paulino, A. C., Ritchie, J. M., Mayr, N. A. and Buatti, J. M. (2003). Presentation, prognostic factors and patterns of failure in adult rhabdomyosarcoma. In Sarcoma, pp. 1–7.
Singh, S. M., Kongari, N., Cabello-Villegas, J. and Mallela, K. M. G. G. (2010). Missense mutations in dystrophin that trigger muscular dystrophy decrease protein stability and lead to cross-β aggregates. Proc. Natl. Acad. Sci. U. S. A. 107,.
Sirri, V., Leibovitch, M. P. and Leibovitch, S. A. (2003). Muscle regulatory factor MRF4 activates differentiation in rhabdomyosarcoma RD cells through a positive-acting C-terminal protein domain. Oncogene 22, 5658–5666.
Soleimani, V. D. and Rudnicki, M. A. (2011). New Insights into the Origin and the Genetic Basis of Rhabdomyosarcomas. Cancer Cell 19, 157–159.
Spehrs-Ciaffi, V., Fitting, J. W., Cotting, J. and Jeannet, P. Y. (2009). Respiratory surveillance of patients with Duchenne and Becker muscular dystrophy. J. Pediatr. Rehabil. Med. 2, 115–122.
Stone, M. R., O’Neill, A., Catino, D. and Bloch, R. J. (2005). Specific interaction of the actin-binding domain of dystrophin with intermediate filaments containing keratin 19. Mol. Biol. Cell 16, 4280–4293.
Suárez-Sánchez, R. and Cisneros, B. (2016). Dystrophin Dp71, a novel tumor suppressor? J. Xiangya Med. 1, 13–13.
Sugihara, H., Teramoto, N., Yamanouchi, K., Matsuwaki, T. and Nishihara, M. (2018). Oxidative stress-mediated senescence in mesenchymal progenitor cells causes the loss of their fibro/adipogenic potential and abrogates myoblast fusion. Aging (Albany. NY). 10, 747–763.
Suzuki, A., Yoshida, M. and Ozawa, E. (1995). Mammalian α1- and β1- syntrophin bind to the alternative splice-prone region of the dystrophin COOH terminus. J. Cell Biol. 128, 373–381.
Tadayoni, R., Rendon, A., Soria-Jasso, L. E. and Cisneros, B. (2012). Dystrophin Dp71: The smallest but multifunctional product of the duchenne muscular dystrophy gene. Mol. Neurobiol. 45, 43–60.
Takahashi, Y., Oda, Y., Kawaguchi, K. I., Tamiya, S., Yamamoto, H., Suita, S. and Tsuneyoshi, M. (2004). Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod. Pathol. 17, 660–669.
Talsness, D. M., Belanto, J. J. and Ervasti, J. M. (2015). Diseaseproportional proteasomal degradation of missense dystrophins. Proc. Natl. Acad. Sci. U. S. A. 112, 12414–12419.
Tan, S., Tan, S., Chen, Z., Cheng, K., Chen, Z., Wang, W., Wen, Q. and Zhang, W. (2016a). Knocking down Dp71 expression in A549 cells reduces its malignancy in vivo and in vitro. Cancer Invest. 34, 16–25.
Tan, S., Tan, J., Tan, S., Zhao, S., Cao, X., Chen, Z., Weng, Q., Zhang, H., Wang, K. K., Zhou, J., et al. (2016b). Decreased Dp71 expression is associated with gastric adenocarcinoma prognosis. Oncotarget 7, 53702–53711.
Tanaka, H., Ishiguro, T., Eguchi, C., Saito, K. and Ozawa, E. (1991). Expression of a dystrophin-related protein associated with the skeletal muscle cell membrane. Histochemistry 96, 1–5.
Tanihata, J., Nagata, T., Ito, N., Saito, T., Nakamura, A., Minamisawa, S., Aoki, Y., Ruegg, U. T. and Takeda, S. (2018). Truncated dystrophin ameliorates the dystrophic phenotype of mdx mice by reducing sarcolipin-mediated SERCA inhibition. Biochem. Biophys. Res. Commun. 505, 51–59.
Tchkonia, T., Zhu, Y., Van Deursen, J., Campisi, J. and Kirkland, J. L. (2013). Cellular senescence and the senescent secretory phenotype:
Therapeutic opportunities. J. Clin. Invest. 123, 966–972.
Tiffin, N., Williams, R. D., Shipley, J. and Pritchard-Jones, K. (2003). PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Br. J. Cancer 89, 327–332.
Toussaint, M., Soudon, P. and Kinnear, W. (2008). Effect of non-invasive ventilation on respiratory muscle loading and endurance in patients with Duchenne muscular dystrophy. Thorax 63, 430–434.
Troy, A., Cadwallader, A. B., Fedorov, Y., Tyner, K., Tanaka, K. K. and Olwin, B. B. (2012). Coordination of satellite cell activation and selfrenewal by par-complex-dependent asymmetric activation of p38α/β MAPK. Cell Stem Cell 11, 541–553.
Tuffery-Giraud, S., Béroud, C., Leturcq, F., Yaou, R. Ben, Hamroun, D., Michel-Calemard, L., Moizard, M. P., Bernard, R., Cossée, M., Boisseau, P., et al. (2009). Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: A model of nationwide knowledgebase. Hum. Mutat. 30, 934–945.
Turner, P. R., Westwood, T., Regen, C. M. and Steinhardt, R. A. (1988). Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice. Nature 335, 735–738.
Vaira, V., Faversani, A., Dohi, T., Maggioni, M., Nosotti, M., Tosi, D., Altieri, D. C. and Bosari, S. (2011). Aberrant overexpression of the cell polarity module Scribble in human cancer. Am. J. Pathol. 178, 2478–2483.
Van Den Bergen, J. C., Wokke, B. H., Janson, A. A., Van Duinen, S. G., Hulsker, M. A., Ginjaar, H. B., Van Deutekom, J. C., Aartsma-Rus, A., Kan, H. E. and Verschuuren, J. J. G. M. (2014). Dystrophin levels and clinical severity in Becker muscular dystrophy patients. J. Neurol. Neurosurg. Psychiatry 85, 747–753.
van der Pijl, E. M., van Putten, M., Niks, E. H., Verschuuren, J. J. G. M. G. M., Aartsma-Rus, A. and Plomp, J. J. (2016). Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models. Eur. J. Neurosci. 43, 1623–1635.
Vila, M. C., Klimek, M. B., Novak, J. S., Rayavarapu, S., Uaesoontrachoon, K., Boehler, J. F., Fiorillo, A. A., Hogarth, M. W., Zhang, A., Shaughnessy, C., et al. (2015). Elusive sources of variability of dystrophin rescue by exon skipping. Skelet. Muscle 5,.
Villarreal-Silva, M., Suárez-Sánchez, R., Rodríguez-Muñoz, R., Mornet, D. and Cisneros, B. (2010). Dystrophin Dp71 is critical for stability of the DAPs in the nucleus of PC12 cells. Neurochem. Res. 35, 366–373.
Waaijer, M. E. C., Parish, W. E., Strongitharm, B. H., van Heemst, D., Slagboom, P. E., de Craen, A. J. M., Sedivy, J. M., Westendorp, R. G. J., Gunn, D. A. and Maier, A. B. (2012). The number of p16INK4a positive cells in human skin reflects biological age. Aging Cell 11, 722–725.
Wang, Y., Marino-Enriquez, A., Bennett, R. R., Zhu, M., Shen, Y., Eilers, G., Lee, J. C., Henze, J., Fletcher, B. S., Gu, Z., et al. (2014). Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat. Genet. 46, 601–606.
Warner, L. E. (2002). Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy. Hum. Mol. Genet. 11, 1095–1105.
Wein, N., Vulin, A., Falzarano, M. S., Szigyarto, C. A. K., Maiti, B., Findlay, A., Heller, K. N., Uhlén, M., Bakthavachalu, B., Messina, S., et al. (2014). Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. Nat. Med. 20, 992–1000.
Wilson, K., Faelan, C., Patterson-Kane, J. C., Rudmann, D. G., Moore, S. A., Frank, D., Charleston, J., Tinsley, J., Young, G. D. and Milici, A. J. (2017). Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification. SAGE Publications Inc.
Wright, W. E., Sassoon, D. A. and Lin, V. K. (1989). Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD. Cell 56, 607–617.
Yokota, T., Lu, Q. L., Partridge, T., Kobayashi, M., Nakamura, A., Takeda, S. and Hoffman, E. (2009). Efficacy of systemic morpholino exonskipping in duchenne dystrophy dogs. Ann. Neurol. 65, 667–676.
Zhao, J., Kodippili, K., Yue, Y., Hakim, C. H., Wasala, L., Pan, X., Zhang, K., Yang, N. N., Duan, D. and Lai, Y. (2016). Dystrophin contains multiple independent membrane-binding domains. Hum. Mol. Genet. 25, 3647–3653.
論文の公開元へ
